SYK
STRYKER CORP
NYSE · Healthcare · Medical - Devices · US
$298.00
+1.13%Year over year
Reported trailing growth
- Revenue
- +8.5%
- EBITDA
- +40.7%
- EBIT
- +10.2%
- EPS
- +27.2%
- Free cash flow
- +16.8%
- Operating cash flow
- +15.9%
Forward estimates
Based on analyst estimates
- Revenue
- +11.8%
- EBITDA
- +43.0%
- EPS
- +68.3%
Three-year CAGR
- Revenue
- +10.8%
- EBITDA
- +16.3%
- EBIT
- +9.4%
- Net income
- +11.2%
- EPS
- +10.9%
- Free cash flow
- +28.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026